How good is the neosquamous epithelium?

Digestive Diseases

Volumn 32, Issue 1-2, 2014, Pages 164-170

  Orlando, Roy C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Barrett's esophagus; Claudin 4; Neosquamous epithelium; Tight junction

Indexed keywords

CLAUDIN 4; ESOMEPRAZOLE; FLUORESCEIN; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTRIC RESISTANCE; ENDOSCOPIC BIOPSY; ESOPHAGUS BIOPSY; ESOPHAGUS FUNCTION; ESOPHAGUS MUCOSA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; INTERCELLULAR SPACE; MALE; MICROSCOPY; MIDDLE AGED; MORPHOMETRICS; NEOSQUAMOUS EPITHELIUM; PERMEABILITY BARRIER; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SQUAMOUS EPITHELIUM; YOUNG ADULT; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; ESOPHAGEAL ADENOCARCINOMA; PROTEIN EXPRESSION; TIGHT JUNCTION;

ADOLESCENT; ADULT; AGED; BARRETT ESOPHAGUS; CLAUDINS; ELECTRIC IMPEDANCE; EPITHELIUM; ESOPHAGUS; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84896107769     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000357185     Document Type: Article

References (71)

1. Shaheen NJ, Richter JE: Barrett's oesophagus. Lancet 2009; 373: 850-861.
2. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, Hunter J, Jankowski J, Lundell L, Reid B, Shaheen NJ, Sonnenberg A, Wang K, Weinstein W: A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-330. (Pubitemid 38962298)
3. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P: Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365: 1375-1383.
4. Kahrilas PJ, Pandolfino JE: Gastroesophageal reflux disease and its complications, including Barrett's metaplasia; in Feldman MJ, Friedman LS, Sleisenger MH (eds): Gastrointestinal and Liver Disease: Pathophysiology/ Diagnosis/Management. Philadelphia, Saunders, 2002, vol 1, pp 599-622.
5. Weinstein WM: Is Barrett's esophagus dangerous? Endoscopy 2002; 34: 1007-1009. (Pubitemid 35446333)
6. Eckardt VF, Kanzler G, Bernhard G: Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111: 33-37. (Pubitemid 32635259)
7. Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR: Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc 2005; 62: 842-848. (Pubitemid 41654416)
8. Roorda AK, Marcus SN, Triadafilopoulos G: Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus 2007; 20: 516-522. (Pubitemid 47617837)
9. Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW: Endoscopic ablation of Barrett's oesophagus: a randomizedcontrolled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004; 20: 1289-1296. (Pubitemid 40040075)
10. Sampliner RE: Endoscopic therapy for Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7: 716-720.
11. Odze RD, Lauwers GY: Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy. Endoscopy 2008; 40: 1008-1015.
12. Abbas G, Pennathur A, Keeley SB, Landreneau RJ, Luketich JD: Laser ablation therapies for Barrett's esophagus. Semin Thorac Cardiovasc Surg 2005; 17: 313-319.
13. Triadafilopoulos G: Acid and bile reflux in Barrett's esophagus: a tale of two evils. Gastroenterology 2001; 121: 1502-1506.
14. Roorda AK, Triadafilopoulos G: Circumferential and focal radiofrequency ablation for the treatment of Barrett's esophagus. Expert Rev Gastroenterol Hepatol 2008; 2: 627-634.
15. Yeh RW, Triadafilopoulos G: Endoscopic therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am 2005; 15: 377-397, vii.
16. Paulson TG, Xu L, Sanchez C, Blount PL, Ayub K, Odze RD, Reid BJ: Neosquamous epithelium does not typically arise from Barrett's epithelium. Clin Cancer Res 2006; 12: 1701-1706.
17. Weston AP: Automated circumferential Barrett's ablation by using radiofrequency energy: a welcome step in the right direction. Gastrointest Endosc 2007; 65: 196-199. (Pubitemid 46157126)
18. Sharma VK, Wang KK, Overholt BF, Lightdale CJ, Fennerty MB, Dean PJ, Pleskow DK, Chuttani R, Reymunde A, Santiago N, Chang KJ, Kimmey MB, Fleischer DE: Balloonbased, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65: 185-195. (Pubitemid 46157125)
19. Bergman JJ: Radiofrequency energy ablation of Barrett's esophagus: the best is yet to come! Gastrointest Endosc 2007; 65: 200-202. (Pubitemid 46148922)
20. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ: Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288.
21. Fleischer DE, Sharma VK: Endoscopic ablation of Barrett's esophagus using the Halo system. Dig Dis 2008; 26: 280-284.
22. Hernandez JC, Reicher S, Chung D, Pham BV, Tsai F, Disibio G, French S, Eysselein VE: Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy 2008; 40: 388-392. (Pubitemid 351696375)
23. Jackson J: RF ablation of intestinal metaplasia (Barrett esophagus). Conf Proc IEEE Eng Med Biol Soc 2004; 7: 5128.
24. Larghi A, Lightdale CJ, Ross AS, Fedi P, Hart J, Rotterdam H, Noffsinger A, Memeo L, Bhagat G, Waxman I: Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007; 39: 1086-1091.
25. Garewal H, Ramsey L, Sharma P, Kraus K, Sampliner R, Fass R: Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol 1999; 94: 2829-2833. (Pubitemid 29482742)
26. Mork H, Al-Taie O, Berlin F, Kraus MR, Scheurlen M: High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol 2007; 42: 23-27. (Pubitemid 46033042)
27. Madisch A, Miehlke S, Bayerdorffer E, Wiedemann B, Antos D, Sievert A, Vieth M, Stolte M, Schulz H: Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation. World J Gastroenterol 2005; 11: 1182-1186. (Pubitemid 40353006)
28. Pech O, Behrens A, May AD, Nachbar L, Gossner L, Rabenstein T, Manner H, Guenter E, Huijsmans J, Vieth M, Stolte M, Ell C: Longterm results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 58: 1200-1206.
29. Ferraris R, Fracchia M, Foti M, Sidoli L, Taraglio S, Vigano L, Giaccone C, Rebecchi F, Meineri G, Senore C, Pera A: Barrett's oesophagus: long-term follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther 2007; 25: 835-840. (Pubitemid 46434909)
30. Basu KK, Pick B, Bale R, West KP, de Caestecker JS: Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 2002; 51: 776-780. (Pubitemid 35408594)
31. Michopoulos S, Tsibouris P, Bouzakis H, Sotiropoulou M, Kralios N: Complete regression of Barrett's esophagus with heat probe thermocoagulation: mid-term results. Gastrointest Endosc 1999; 50: 165-172. (Pubitemid 29380360)
32. Kahaleh M, Van Laethem JL, Nagy N, Cremer M, Deviere J: Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002; 34: 950-955. (Pubitemid 35446323)
33. Orlando RC: Mucosal defense in Barrett's esophagus; in Sharma P, Sampliner R (eds): Barrett's Esophagus and Esophageal Adenocarcinoma, ed 2. Malden, Blackwell Publishing, 2006.
34. Fass R, Yalam JM, Camargo L, Johnson C, Garewal HS, Sampliner RE: Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett's esophagus. Dig Dis Sci 1997; 42: 1853-1858. (Pubitemid 27433532)
35. Johnson DA, Winters C, Spurling TJ, Chobanian SJ, Cattau EL Jr: Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 9: 23-27. (Pubitemid 17035252)
36. Gerson LB, Shetler K, Triadafilopoulos G: Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig Liver Dis 2005; 37: 651-658. (Pubitemid 44356081)
37. Hornick JL, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD: Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. Am J Surg Pathol 2005; 29: 372-380. (Pubitemid 40321974)
38. Hornick JL, Mino-Kenudson M, Lauwers GY, Liu W, Goyal R, Odze RD: Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol 2008; 103: 38-47.
39. Jankowski JA, Anderson M: Review article: management of oesophageal adenocarcinoma-control of bile and inflammation in intervention strategies for Barrett's oesophagus. Aliment Pharmacol Ther 2004; 20(suppl 5): 71-80, discussion 95-96. (Pubitemid 39424912)
40. Yoshida N: Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr 2007; 40: 13-23. (Pubitemid 46449683)
41. Eksteen JA, Scott PA, Perry I, Jankowski JA: Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFalpha. Eur J Cancer Prev 2001; 10: 163-166. (Pubitemid 32291638)
42. Souza RF, Shewmake K, Pearson S, Sarosi GA Jr, Feagins LA, Ramirez RD, Terada LS, Spechler SJ: Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2004; 287:G743-G748. (Pubitemid 39280431)
43. Souza RF, Morales CP, Spechler SJ: Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 2001; 15: 1087-1100. (Pubitemid 32677075)
44. Reid BJ, Blount PL, Feng Z, Levine DS: Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 3089-3096.
45. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J: Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000; 46: 574-577. (Pubitemid 30305825)
46. Sampliner RE, Fass R: Partial regression of Barrett's esophagus-an inadequate endpoint. Am J Gastroenterol 1993; 88: 2092-2094. (Pubitemid 23352177)
47. Familiari L, Scaffidi M, Bonica M, Consolo P, Giacobbe G, Fichera D, Familiari P: Endoscopic treatment of Barrett's epithelium with argon plasma coagulation. Long-term followup. Minerva Gastroenterol Dietol 2003; 49: 63-70. (Pubitemid 36505761)
48. Zhou C, Tsai TH, Lee HC, et al: Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). Gastrointest Endosc 2012; 76: 32-40.
49. Bruewer M, Samarin S, Nusrat A: Inflammatory bowel disease and the apical junctional complex. Ann NY Acad Sci 2006; 1072: 242-252. (Pubitemid 44448457)
50. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC: Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002; 34: 385-396.
51. Orlando RC: Pathogenesis of reflux esophagitis and Barrett's esophagus; in Cappell MS (ed): Medical Clinics of North America. Philadelphia, WB Saunders, 2005, vol 89, pp 219-242.
52. Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC: Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol 2004; 99: 13-22. (Pubitemid 38679095)
53. Orlando RC: Gastroesophageal reflux disease: Offensive factors and tissue resistance; in Orlando RC (ed): Gastroesophageal Reflux Disease. New York, Marcel Dekker, 2000, pp 165-192.
54. Orlando RC, Bryson JC, Powell DW: Mechanisms of H+ injury in rabbit esophageal epithelium. Am J Physiol 1984; 246:G718-G724. (Pubitemid 14079072)
55. Tobey NA, Carson JL, Alkiek RA, Orlando RC: Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996; 111: 1200-1205. (Pubitemid 26362244)
56. Calabrese C, Bortolotti M, Fabbri A, Areni A, Cenacchi G, Scialpi C, Miglioli M, Di Febo G: Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005; 100: 537-542. (Pubitemid 40487549)
57. Caviglia R, Ribolsi M, Maggiano N, Gabbrielli AM, Emerenziani S, Guarino MP, Carotti S, Habib FI, Rabitti C, Cicala M: Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005; 100: 543-548. (Pubitemid 40487550)
58. Solcia E, Villani L, Luinetti O, Trespi E, Strada E, Tinelli C, Fiocca R: Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch 2000; 436: 207-216. (Pubitemid 30168678)
59. Kahrilas PJ: Dilated intercellular spaces: extending the reach of the endoscope. Am J Gastroenterol 2005; 100: 549-550. (Pubitemid 40487551)
60. Khalbuss WE, Marousis CG, Subramanyam M, Orlando RC: Effect of HCl on transmembrane potentials and intracellular pH in rabbit esophageal epithelium. Gastroenterology 1995; 108: 662-672.
61. Tobey NA, Orlando RC: Mechanisms of acid injury to rabbit esophageal epithelium. Role of basolateral cell membrane acidification. Gastroenterology 1991; 101: 1220-1228.
62. Tobey NA, Reddy SP, Keku TO, Cragoe EJ Jr, Orlando RC: Mechanisms of HCl-induced lowering of intracellular pH in rabbit esophageal epithelial cells. Gastroenterology 1993; 105: 1035-1044. (Pubitemid 23281490)
63. Tobey NA, Cragoe EJ Jr, Orlando RC: HClinduced cell edema in rabbit esophageal epithelium: a bumetanide-sensitive process. Gastroenterology 1995; 109: 414-421.
64. Allende DS, Yerian LM: Diagnosing gastroesophageal reflux disease: the pathologist's perspective. Adv Anat Pathol 2009; 16: 161-165.
65. Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC: Defective barrier function in neosquamous epithelium. Am J Gastroenterol 2013; 108: 386-391.
66. Jovov B, Que J, Tobey NA, Djukic Z, Hogan BL, Orlando RC: Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterology 2011; 106: 1039-1047.
67. Hou J, Gomes AS, Paul DL, Goodenough DA: Study of claudin function by RNA interference. J Biol Chem 2006; 281: 36117-36123. (Pubitemid 46041345)
68. Jovov B, Van Itallie CM, Shaheen NJ, Carson JL, Gambling TM, Anderson JM, Orlando RC: Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. Am J Physiol Gastrointest Liver Physiol 2007; 293:G1106-G1113. (Pubitemid 350255034)
69. Van Itallie C, Rahner C, Anderson JM: Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. J Clin Invest 2001; 107: 1319-1327. (Pubitemid 32494549)
70. Sifrim D: Acid, weakly acidic and non-acid gastro-oesophageal reflux: differences, prevalence and clinical relevance. Eur J Gastroenterol Hepatol 2004; 16: 823-830. (Pubitemid 39179648)
71. Fass R, Gasiorowska A: Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10: 252-257.